Onasemnogene abeparvovec-xioi: a gene replacement strategy for the treatment of infants diagnosed with spinal muscular atrophy.
Drugs Today (Barc)
; 57(6): 387-399, 2021 Jun.
Article
in En
| MEDLINE
| ID: mdl-34151905
ABSTRACT
In May of 2019, the adeno-associated virus (AAV)-based gene therapy onasemnogene abeparvovec-xioi (Zolgensma) became the second Food and Drug Administration (FDA)-approved gene therapy with designated use for infants diagnosed with spinal muscular atrophy (SMA). The decision came nearly 10 years after results of the first preclinical models were initially reported. While the journey was an arduous one, the approval was an indication of the remarkable success of the first in-human clinical trials. According to the traditional classification system of autosomal recessive SMA, of which there are multiple types with phenotypic variability, SMA type 1 is the most common and most severe and represents 45% of the SMA patient population. Children with SMA type 1 cannot lift their heads without assistance and do not live past their second birthday. With Zolgensma, the first treated children with SMA type 1 have reached 5 years of age and some of them achieved the ability to sit unassisted or even walk. In this article, we review the work that led to FDA approval with emphasis on the development of preclinical and clinical studies.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Muscular Atrophy, Spinal
/
Spinal Muscular Atrophies of Childhood
Type of study:
Diagnostic_studies
/
Prognostic_studies
Limits:
Child
/
Humans
/
Infant
Country/Region as subject:
America do norte
Language:
En
Journal:
Drugs Today (Barc)
Journal subject:
MEDICINA OCUPACIONAL
/
SAUDE AMBIENTAL
Year:
2021
Document type:
Article
Affiliation country:
United States